Axsome Therapeutics, Inc. (AXSM)
| Market Cap | 3.28B |
| Revenue (ttm) | 223.44M |
| Net Income (ttm) | -201.83M |
| Shares Out | 47.32M |
| EPS (ttm) | -4.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 546,161 |
| Open | 68.99 |
| Previous Close | 68.59 |
| Day's Range | 67.92 - 71.25 |
| 52-Week Range | 53.71 - 91.29 |
| Beta | 1.94 |
| Analysts | Strong Buy |
| Price Target | 107.13 (+54.48%) |
| Earnings Date | Nov 6, 2023 |
About AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price forecast is $107.13, which is an increase of 54.48% from the latest price.
News
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system...
AXSM FINAL DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
NEW YORK , Nov. 26, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds investors of the common stock of Axsome Therapeutics, Inc. ("Axsome") (NASDAQ: AXSM) of the re...
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system...
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system...
ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
NEW YORK , Nov. 20, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds investors of the common stock of Axsome Therapeutics, Inc. ("Axsome") (NASDAQ: AXSM) of the re...
Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers – AXSM
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm announces the reopening of the lead plaintiff appointment process in a class action lawsuit against Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NAS...
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Total 3Q 2023 product revenue of $57.8 million, representing 244% year-over-year growth Auvelity ® 3Q 2023 net product sales of $37.7 million, representing 36% quarter-over-quarter growth Sunosi ® 3Q ...
Axsome Therapeutics and the Global Alzheimer's Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer's Disease Awareness Month 2023
Axsome's headquarters to be lit in teal as part of the Alzheimer's Foundation of America awareness campaign Axsome's headquarters to be lit in teal as part of the Alzheimer's Foundation of America awa...
Axsome Therapeutics to Present at Upcoming Investor Conferences
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system...
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Conference
NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system...
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time
Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system...
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (NASDAQ: AXSM) on ...
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste...
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
Data presentations explore effects on patient-centric efficacy measures of treatments for patients with depression, and excessive sleepiness associated with obstructive sleep apnea and narcolepsy
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Total 2Q 2023 product revenue of $46.7 million Auvelity ® 2Q 2023 net product sales of $27.6 million, representing 76% quarter-over-quarter growth Sunosi ® 2Q 2023 net product revenue of $19.1 million...
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern Time Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern Time
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system...
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the manageme...
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the manageme...
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing novel therapies for the management of central n...
Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apnea Cognitive improvement with Sunosi sustained over eight hours i...
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Data on Auvelity demonstrating improved functioning in major depressive disorder Data on Sunosi demonstrating improved cognitive function in patients with excessive daytime sleepiness associated with ...
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
Auvelity ® 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net product sales of $28.6 million Total 1Q 2023 revenue of $94.6 million, including Sunosi ® ex-U.S. license agreement upfront paym...
Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference
NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system ...